


**GUIDE** *nano* 



National Institute for Public Health  
and the Environment  
*Ministry of Health, Welfare and Sport*

# Development of a risk assessment strategy within the GUIDEnano project

Dr. Susan Wijnhoven  
RIVM  
Sustainable Nanotechnology  
Conference 2015

Development of a risk assessment strategy within the  
GUIDEnano project | March 10, 2015

## Universities & Research Centers



## Industry




Develop innovative methodologies to evaluate and manage human and environmental health risks of NM-enabled products, considering the whole product life cycle




**Interactive digital Guidance Tool**


### THE TARGET


#### NM-enabled product Life Cycle





### SCOPE OF THE GUIDANCE















- Risk assessment decision flow:
  - Divided in 4 main elements
    - Input and information requirements (exposure and hazard assessment)
    - Risk assessment (calculation of risk and classification into 3 categories)
    - Recommendation for follow-up actions (reduction of uncertainty, risk mitigation)
    - Output report





‘Risk characterisation ratio’ (RCR):


$$\frac{\textit{exposure}}{\textit{hazard value}}$$

- Exposure:
  - relevant exposure routes/ duration
  - model output, exposure libraries, direct measurement data
- Hazard:
  - relevant endpoints with (if possible) quantitative exposure estimate with uncertainty

- Identification of human hazard endpoints to be addressed for each exposure scenario

route	duration	endpoints to be evaluated	Endpoints	Quantitative ?	
inhalation	single	1,3,4,6, 7	1	Irritation/corrosion	N
	repeated	1,2,3,5,6,7,8	2	sensitisation	N
dermal	single	1,3,4,6, 7	3	absorption/accumulation/elimination	Y
	repeated	1,2,3,5,6,7,8	4	acute toxicity	Y
oral	single	1,3,4,6,7	5	repeated dose toxicity	Y
	repeated	1,2,3,5,6,7,8	6	mutagenicity	N
			7	carcinogenicity	N/Y
			8	reproductive and developmental toxicity	Y


# GUIDE *nano*



## Risk assessment qualitative endpoints

Yes/No answer with uncertainty value


Exposure		YES			NO		
Hazard		Low uncertain y	Medium Uncertain y	High uncertain y	Low uncertain y	Medium Uncertain y	High uncertain y
YES	Low uncertain y	Risk			No Risk		
	Medium Uncertain y				No Risk		
	High uncertain y				No Risk		
NO	Low uncertain y	No Risk	No Risk	No Risk	No Risk	No Risk	No Risk
	Medium Uncertain y				No Risk		
	High uncertain y				No Risk		




Uncertainty	Ratio Y/N
Low	70-90 / 10-30
Medium	50-70 / 30-50
High	50/50



## What risk is “acceptable”?



$\frac{\text{exposure}}{\text{hazard value}}$



*Change from acceptable to “probability of risk”*

*Defaults:*


Acceptable risk, low probability of risk : <5% probability on a ratio of > 1.

Possible risk, medium probability of risk: 5-75% probability on a ratio of > 1.


Unacceptable risk, high probability of risk: >75% probability on a ratio of > 1



### Possible risk: reduction of risk or reduction of uncertainty



### Unacceptable risk: reduction of risk



## Future work: risk assessment

- Continue with tool development
- Discuss and review definition of (acceptable) risk
- Further development of uncertainty/ sensitivity analysis
- Definition of content of output report
- Stakeholder analysis of tool
- Validation with case studies

- GUIDEnano project consortium
  - All partners
    - Gemma Janer (LEITAT)
    - Socorro Vazquez (LEITAT)
    - Margriet Park (RIVM)
    - Ralph Vanhauten (TW)
    - Lion Traas (TW)
  - WP7
    - Petra van Kesteren (RIVM)
    - Maria Luisa Cruz- Fernandez (INIA)
    - Derk Brouwer (TNO)
    - Thies Oosterwijk (TNO)
    - Joost Westerhout (TNO)
    - Manoj Vaghela (Pinsent Masons)

# GUIDE *nano*





Measured data can be summarized with an average value and standard deviation. This is the **variance** in the data.

Extrapolation of the data (e.g. from one scenario to the next, or from animals to humans) will introduce **uncertainty**.

Model estimation of parameter values will also introduce **uncertainty**.

Introduced level of uncertainty		SCENARIO		
		IDENTICAL	COMPARABLE	DIFFERENT
SUBSTANCE	IDENTICAL	None	Low	High
	COMPARABLE	Medium	Medium/High	High/Very high
	DIFFERENT	High	High/Very high	Very high

- What is considered as “high” uncertainty? A 10-fold deviation? Or a 1000-fold deviation? The level of uncertainty needs to be quantifiable.



Uncertainty when defining the appropriate reference scenario